Literature DB >> 34569275

Social, Epidemiological, and Virological Characteristics from Peruvian Subjects Living with HIV-1/AIDS with Different Sexual Risk Behavior.

Carlos Augusto Yabar1,2, Giovanny Francesco Vilcarino1, Susan Espetia1, Fiorela Lujan1, Andres Vásquez-Domínguez1, Mariela Yaya1, Maribel Acuña1, Daniel Santos1, Edgardo Mamani1, Rafael Rodriguez-Bayona3, Javier Salvatierra4, George Obregon1, Soledad Romero1, Fany Cardenas1, Pablo Lopez5, Vanessa Rivera-Amill5.   

Abstract

HIV-1 genetic diversity and resistance profile might change according to the risky sexual behavior of the host. To show this, we recruited 134 individuals between the years 2015 and 2017 identified as transgender women sex workers (TWSW, n = 73) and Heterosexual Military Officers (HET-MO, n = 61). After obtaining informed consent, we collected a blood sample to perform the HIV genotyping, CD4 cell count, and viral load. We used bioinformatics approaches for detecting resistance mutations and recombination events. Epidemiological data showed that both groups reported sexually transmitted diseases and they were widespread among TWSW, especially syphilis and herpes virus (35.6%). Illegal drugs consumption was higher among TWSW (71.2%), whereas condom use was inconsistent for both HET-MO (57.4%) and TWSW (74.0%). TWSW showed the shortest time exposition to antiretroviral therapy (ART) (3.5 years) and the lowest access to ART (34.2%) that conducted treatment failure (>4 logs). HIV-1 sequences from TWSW and HET-MO were analyzed to determine the genetic diversity and antiretroviral drug resistance. Phylogeny analysis revealed 125 (93%) cases of subtype B, 01 subtype A (0.76%), 07 (5.30%) BF recombinants, and 01 (0.76%) AG recombinant. Also, TWSW showed a higher recombination index (9.5%, 7/73) than HET-MO (1.5%, 1/68). HET-MO only showed acquired resistance (26.23%, 16/61), whereas TWSW showed both acquired as transmitted resistance (9.59% for each). In conclusion, TWSW and HET-MO showed significant differences considering the epidemiological characteristics, genetic diversity, recombination events, and HIV resistance profile.

Entities:  

Keywords:  HIV; antiretroviral therapies; molecular biology; virus evolution/diversity

Mesh:

Year:  2021        PMID: 34569275      PMCID: PMC9206475          DOI: 10.1089/AID.2021.0067

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  43 in total

1.  Analysis of HIV type 1 BF recombinant sequences from South America dates the origin of CRF12_BF to a recombination event in the 1970s.

Authors:  Dario A Dilernia; Leandro R Jones; Maria A Pando; Roberto D Rabinovich; Gabriel D Damilano; Gabriela Turk; Andrea E Rubio; Sandra Pampuro; Manuel Gomez-Carrillo; Horacio Salomón
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-03       Impact factor: 2.205

2.  Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.

Authors:  Elena Capel; Glòria Martrus; Mariona Parera; Bonaventura Clotet; Miguel Angel Martínez
Journal:  J Gen Virol       Date:  2012-08-29       Impact factor: 3.891

3.  Prevalences, genotypes, and risk factors for HIV transmission in South America.

Authors:  Silvia M Montano; Jose L Sanchez; Alberto Laguna-Torres; Paloma Cuchi; Maria M Avila; Mercedes Weissenbacher; Margarita Serra; Jose Viñoles; Jose C Russi; Nicolas Aguayo; Adolfo H Galeano; Alberto Gianella; Ronald Andrade; Anabella Arredondo; Eugenio Ramirez; Maria E Acosta; Aracely Alava; Orlando Montoya; Angel Guevara; Hugo Manrique; Jorge L Sanchez; Javier R Lama; Fernando de la Hoz; Gloria I Sanchez; Claudia Ayala; Maria E Pacheco; Gladys Carrion; Gloria Chauca; Juan J Perez; Monica Negrete; Kevin L Russell; Christian T Bautista; James G Olson; Douglas M Watts; Deborah L Birx; Jean K Carr
Journal:  J Acquir Immune Defic Syndr       Date:  2005-09-01       Impact factor: 3.731

Review 4.  Sex work and HIV status among transgender women: systematic review and meta-analysis.

Authors:  Don Operario; Toho Soma; Kristen Underhill
Journal:  J Acquir Immune Defic Syndr       Date:  2008-05-01       Impact factor: 3.731

5.  The possible contribution of HIV-1-induced syncytia to the generation of intersubtype recombinants in vitro.

Authors:  Megan C Steain; Bin Wang; Nitin K Saksena
Journal:  AIDS       Date:  2008-05-31       Impact factor: 4.177

6.  Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution.

Authors:  Bram Vrancken; Guy Baele; Anne-Mieke Vandamme; Kristel van Laethem; Marc A Suchard; Philippe Lemey
Journal:  AIDS       Date:  2015-07-31       Impact factor: 4.177

7.  Polymorphism, recombination, and mutations in HIV type 1 gag-infecting Peruvian male sex workers.

Authors:  Carlos Augusto Yabar; Javier Salvatierra; Eberth Quijano
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

8.  The role of recombination for the coevolutionary dynamics of HIV and the immune response.

Authors:  Rafal Mostowy; Roger D Kouyos; David Fouchet; Sebastian Bonhoeffer
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

9.  Transgender female sex workers' HIV knowledge, experienced stigma, and condom use in the Dominican Republic.

Authors:  Henna Budhwani; Kristine R Hearld; Julia Hasbun; Rebecca Charow; Santo Rosario; Louise Tillotson; Elaine McGlaughlin; John Waters
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

10.  Short-Term Dynamic and Local Epidemiological Trends in the South American HIV-1B Epidemic.

Authors:  Dennis Maletich Junqueira; Rubia Marília de Medeiros; Tiago Gräf; Sabrina Esteves de Matos Almeida
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

View more
  1 in total

Review 1.  HIV and Substance Use in Latin America: A Scoping Review.

Authors:  Hanalise V Huff; Paloma M Carcamo; Monica M Diaz; Jamie L Conklin; Justina Salvatierra; Rocio Aponte; Patricia J Garcia
Journal:  Int J Environ Res Public Health       Date:  2022-06-12       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.